An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

This study tests an experimental drug called CND261 in people with seropositive rheumatoid arthritis (RA) — a type of RA confirmed by specific blood markers — whose disease has not been adequately controlled despite previous treatments. **You may be eligible if:** - You are between 18 and 75 years old - You have adult-onset rheumatoid arthritis confirmed by your doctor - Your RA is moderately to severely active - Prior treatments have not worked well enough - Your other medications are stable - You are in RA disease class I, II, or III (functional ability) **You may NOT be eligible if:** - You have an active infection - You have received a live vaccine within 4 weeks - You have another autoimmune disease at the same time - You have a history of serious blood-clotting disorder, neurological disease, or progressive brain infection - You have had cancer within the past 5 years - You have severe mental illness, dementia, or substance abuse - You have had a major surgery requiring general anesthesia in the past 12 weeks - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.